aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-10-09 20:24Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. due to misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study [1][2][3]. Company Information - aTyr Pharma, Inc. is facing legal action for allegedly providing false and misleading information to investors about the drug Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [2]. - The company announced disappointing results from the EFZO-FIT study on September 15, 2025, revealing that it did not meet its primary endpoint related to mean daily OSC dose reduction at week 48 [3]. Stock Performance - Following the announcement of the study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a significant decline of 83.2% in just one day [4]. Legal Context - Investors who purchased aTyr's common stock between January 16, 2025, and September 12, 2025, are eligible to participate in the class action lawsuit, with a deadline to request lead plaintiff status by December 8, 2025 [4]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].